- Recce Pharmaceuticals (ASX:RCE) inks an MOU with PT Etana Biotechnologies, a leading biomedical organisation in Indonesia
- The partnership aims to drive the clinical development of Recce’s anti-infective portfolio in Indonesia and contribute to the global effort to combat antimicrobial resistance
- RCE last traded at 48 cents
Recce Pharmaceuticals (ASX:RCE) has inked a memorandum of understanding (MOU) with PT Etana Biotechnologies, a leading biomedical organisation in Indonesia.
The collaboration aims to drive the clinical development of Recce’s anti-infective portfolio in Indonesia and contribute to the global effort to combat antimicrobial resistance.
“Health science and biomedicine is an important area in Indonesia’s research and innovation. We need to build a national capability, especially after the lesson of the recent pandemic.” BRIN Chair Laksana Tri Handoko said.
“This collaboration is a continuation of the close relationship we have with Australia, which I see will grow moving forward.
“We want to build our expertise together and I look forward to the work to start with us.”
More than 10 per cent of Indonesia’s adult population (19.5 million) deal with diabetes, a condition associated with increased susceptibility to foot infections, urinary tract infections, and surgical site infections.
A recent study showed that 15 per cent of sepsis patients in Indonesian hospitals had a history of diabetes.
The Indonesian Government’s heightened focus on combating infectious diseases and providing the critical demand for innovative solutions underscores the significance of this collaboration.
“This Bilateral Collaboration between Recce and Etana, signifies the Australian and Indonesian Governments’ shared commitment to advancing public health, fostering innovation, and addressing the global challenge of AMR in the Asia Pacific region,” RCE CEO James Graham said.
RCE last traded at 48 cents.
